Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Volamcabtagene Durzigedleucel · CTX130

Cell therapy (CAR-T) · Kills target cells, directed at CD70 and T-cell receptor (TCR) · developed by CRISPR Therapeutics

Phase 1 Most advanced trial (none active)
CRSP Developer
1 Registered trials

What is Volamcabtagene Durzigedleucel?

Volamcabtagene durzigedleucel is an allogeneic T-lymphocyte cell therapy gene-edited with CRISPR-Cas9 to disrupt endogenous TCR and MHC class I expression and to express a chimeric antigen receptor specific for CD70. The CAR-T cells recognize and bind CD70-overexpressing tumor cells, mediating their cytotoxic killing. It is being studied in T-cell lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CTX130
Drug type
Cell therapy (CAR-T)
Targets
CD70 (antigen), T-cell receptor (TCR)
Mechanism
Kills target cells, directed at CD70 and T-cell receptor (TCR)
Therapy area
Oncology
Developer
CRISPR Therapeutics AG (CRSP)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
S5TX5E9EWP

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04502446 Phase 1 T Cell Lymphoma Terminated CRSP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

T Cell Lymphoma

Other drugs acting on CD70

More from CRISPR Therapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CRSP page.

Follow CRSP, the company behind Volamcabtagene Durzigedleucel

See CRSP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CRSP catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.